- Home
- SERV vs CTNM Comparison
SERV vs CTNM Comparison
Compare SERV & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- CTNM
- Stock Information
- Founded
- SERV 2017
- CTNM 2009
- Country
- SERV United States
- CTNM United States
- Employees
- SERV N/A
- CTNM N/A
- Industry
- SERV Industrial Specialties
- CTNM
- Sector
- SERV Consumer Discretionary
- CTNM
- Exchange
- SERV Nasdaq
- CTNM Nasdaq
- Market Cap
- SERV 338.7M
- CTNM 378.7M
- IPO Year
- SERV N/A
- CTNM 2024
- Fundamental
- Price
- SERV $15.46
- CTNM $14.00
- Analyst Decision
- SERV Strong Buy
- CTNM Strong Buy
- Analyst Count
- SERV 3
- CTNM 4
- Target Price
- SERV $14.67
- CTNM $29.25
- AVG Volume (30 Days)
- SERV 8.9M
- CTNM 82.5K
- Earning Date
- SERV 11-07-2024
- CTNM 11-06-2024
- Dividend Yield
- SERV N/A
- CTNM N/A
- EPS Growth
- SERV N/A
- CTNM N/A
- EPS
- SERV N/A
- CTNM N/A
- Revenue
- SERV $1,679,360.00
- CTNM N/A
- Revenue This Year
- SERV $825.10
- CTNM N/A
- Revenue Next Year
- SERV $607.14
- CTNM N/A
- P/E Ratio
- SERV N/A
- CTNM N/A
- Revenue Growth
- SERV 692.32
- CTNM N/A
- 52 Week Low
- SERV $1.77
- CTNM $12.33
- 52 Week High
- SERV $30.00
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- SERV N/A
- CTNM N/A
- Support Level
- SERV N/A
- CTNM N/A
- Resistance Level
- SERV N/A
- CTNM N/A
- Average True Range (ATR)
- SERV 0.00
- CTNM 0.00
- MACD
- SERV 0.00
- CTNM 0.00
- Stochastic Oscillator
- SERV 0.00
- CTNM 0.00
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an advanced, AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.